fig2
From: Role of plasminogen activator inhibitor-1 (PAI-1) in age-related cardiovascular pathophysiology
Figure 2. PAI-1’s role in dyslipidemia and metabolic dysfunction. Hyperinsulinemia elevates PAI-1 levels, which inhibit t-PA interaction with MTP, promoting VLDL assembly in hepatocytes. PAI-1 also upregulates PCSK9 and FGF21, exacerbating dyslipidemia and cardiovascular risk.
